|
|
 |
Beyond Trust - Three Years of Collaboration with the Leibniz Association
When Ascenion started to cooperate with nine institutions from the Leibniz Association in 2005, the partners agreed that fostering relationships with researchers would be one of the most important tasks. "Scientists must believe that it is worthwhile sharing their results with Ascenion," they emphasised when asked for mid-term goals. Today, the question of trust is no longer an issue. more
|
| |
 |
Not being limited to what the pharmaceutical industry offers - that is one of the driving forces in Lars Lindner's professional life. As an oncologist, he is faced with the shortcomings of available therapeutics each daymore
Spinning Innovation
Certus Pharmaceuticals - new shuttles for chemotherapies
| |
 |
Certus is the first spin-out from one of Ascenion's partner institutes to build its new venture in the US. Based in South San Francisco, California, co-founder and CSO Peter Scherrer has already attracted a group of experienced industry managers and drug discovery expertsmore
Protectimmun - stable dust against hay fever and asthma
| |
 |
Protectimmun is the second spin-off from Ascenion's partner institutions in the Leibniz Association that Ascenion has helped get off the ground - just two years after the partners started to collaborate with regards to IP protection and commercialization.more
Turning Science into Business Opportunities
Killing bacteria is not enough
| |
 |
Sepsis - blood poisoning - is a severe form of infection that poses pressing problems in intensive care units. According to the Centers for Disease Control and Prevention, worldwide mortality rates range from 20% for sepsis up to >60% for septic shock. "Sepsis develops when a patient's immune system runs out of control in response to bacterial infection", Prof. Klaus Brandenburg, scientist at the Research Center Borstel (FZB), explains. more
Fostering Networks
From California...
| |
 |
This years' BIO Annual Convention in San Diego, US, was very effective in establishing Ascenion as a premier point of access to life science IP emanating from public research institutions in Germany.more
...to Japan
During this year’s Science and Technology in Society (STS) forum in Kyoto, Japan, over 750 delegates from 91 countries discussed key issues of environmental policy, energy development, food supply, communication technology, intellectual property and technology transfer.more
Biovaria: Germany's top technologies
The first BioVaria, held in Munich in May 2008, brought together more than 150 delegates from international biopharmaceutical companies and Germany's top universities and research institutions. more
3rd Biotech Networkshop: Learn from seasoned managers
Ascenion and Max Planck Innovation are happy to announce their 3rd Biotech Networkshop to be held on 4th-6th March, 2009 at the Evangelische Akademie Tutzing.more
Latest Technology Offers
- New substances for treatment of HIV and HTLV infections
- Specific CD8+ T cell repertoire in HIV long-term nonprogressors
- Novel antibiotics for the treatment of Methicillin-resistant Staphylococcus aureus
- Antibiotic salts suitable for implant coating
- New Macrolactin Antibiotic
- Stabilized Etnangien derivative - drug candidate from myxobacteria
- New highly specific inhibitor of microbial hyaluronate lyase as adjuvant in cosmetic or pharmaceutical formulations
- Novel antibiotics for the treatment of tuberculosis
This Information Letter is periodically published by Ascenion GmbH.
Editor: Ascenion GmbH, Herzogstraße 64,
80803 Munich, Germany
Represented by: Dr Christian A. Stein (CEO)
Register Court: Amtsgericht München HRB 118236
VAT Identification Number: DE 812299325
Text: KONOCOM
Layout: Design Direction
Sources of pictures: Ascenion, BNI, Dr Lindner, HZI, Helmholtz Zentrum München, Photocase, Protectimmun GmbH, STS Forum
Meet us at the forthcoming events:
2008-11-17 to 2008-11-19
BIO-Europe, Mannheim / Heidelberg, Germany
2008-11-28 to 2008-11-29
Doktorandencamp 2008, Headquarters of the Fraunhofer-Gesellschaft and Munich Business School, Munich, Germany
2009-02-10
Seminar on "IP Asset Management - from theory to practice",
Ludwig-Maximilian University, Munich, Germany
2009-03-04 to 2009-03-06
BioTech Networkshop, Tutzing, Germany
2009-05-08
BioVaria, Munich, Germany
News in Brief:
In dialogue with the Wellcome Trust and HTGF
Ascenion invited representatives of the Wellcome Trust and the High-Tech Gründerfonds (HTGF) to learn about some of the most attractive projects from its portfolio. more
"Biting" Antibodies against cancer
Micromet's BiTE® antibodies are designed to activate T cells, the body's most potent "killer" cells, specifically against cancer cells.more
PARF: One idea - many applications
"PARF" (peptide associated with rheumatic fever) is a peptide that is present on certain pathogenic bacteria of the streptococcal family. It was discovered and described by HZI researchersmore
Improving technology transfer in national genome research
With the expiry of the national genome research network (NGFN) at the end of last year, the Federal Ministry of Education and Research restructured its support programme for medical genome research in Germany.more
New employee to support the KompetenzCenter
In May this year, Anja Kroke joined Ascenion to support the activities of the KompetenzCenter.more
Contact us:
Munich:
T +49 89 318814-0
info(at)ascenion.de
Berlin:
T +49 30 9406 230 -1/-4
berlin(at)ascenion.de
Braunschweig:
T +49 531 6181 2090
braunschweig(at)ascenion.de
Hamburg:
T +49 40 22611 278
habeck(at)ascenion.de
Hanover:
T +49 511 5328 921
cordes(at)ascenion.de
Neuherberg:
T +49 89 3187 2850
scheek(at)ascenion.de
Ascenion GmbH, www.ascenion.de